Table 5 Multinomial logistic regression to identify variables that were associated with a greater probability of receiving RAAS blocker or SGLT2 inhibitor versus receiving neither in this population, and receiving the combination of both (complete nephroprotective treatment)

SLGT2^d Inhibitor or RAAS^e blocker

Intersection

-0.57

Gender: male

-0.11

0.02

0.90

0.82

0.98

Age (years)

0.01

0.00

1.01

1.01

1.02

Hypertension

0.85

0.00

2.34

2.13

2.58

Obesity

0.54

0.02

1.72

1.11

2.66

Use of aspirin

0.66

0.00

1.93

1.76

2.12

Use of β-blockers

0.16

0.00

1.18

1.06

1.31

Use of Proton Pump Inhibitors

0.10

0.04

1.11

1.01

1.22

Use of metformin

0.33

0.00

1.39

1.27

1.53

Use of insulin

-0.17

0.00

0.85

0.77

0.93

Be treated in Bogota-Cundinamarca region

ref

ref

ref

Ref

ref

Be treated in the Caribe region

0.05

0.51

1.06

0.90

1.24

Be treated in the Central region

-0.16

0.04

0.85

0.73

0.99

Be treated in the Oriental region

-0.04

0.80

0.96

0.74

1.27

Be treated in the Pacific region

0.25

0.00

1.28

1.12

1.47

Complete treatment (ACEi^f or ARB^g + SGLT2i)

Intersection

-1.29

Gender: male

0.03

0.67

1.03

0.91

1.16

Age (years)

-0.02

0.00

0.98

0.98

0.99

Dementia

-0.54

0.01

0.58

0.38

0.88

Dyslipidemia

0.65

0.00

1.91

1.52

2.40

Hypertension

0.97

0.00

2.63

2.29

3.03

Obesity

1.15

0.00

3.14

1.96

5.05

Use of aspirin

0.93

0.00

2.53

2.23

2.88

Use of β-blockers

0.25

0.00

1.28

1.12

1.47

Use of Proton Pump Inhibitors

0.15

0.02

1.17

1.03

1.32

Use of metformin

0.61

0.00

1.83

1.61

2.08

Use of insulin

0.97

0.00

2.63

2.31

3.00

Be treated in Bogota-Cundinamarca region

ref

ref

ref

Ref

ref

Be treated in the Caribe region

-0.28

0.02

0.76

0.60

0.96

Be treated in the Central region

0.13

0.22

1.14

0.93

1.39

Be treated in the Oriental region

0.13

0.50

1.13

0.79

1.63

Be treated in the Pacific region

0.54

0.00

1.72

1.44

2.07